KR101848819B1 - Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체 - Google Patents

Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체 Download PDF

Info

Publication number
KR101848819B1
KR101848819B1 KR1020157036007A KR20157036007A KR101848819B1 KR 101848819 B1 KR101848819 B1 KR 101848819B1 KR 1020157036007 A KR1020157036007 A KR 1020157036007A KR 20157036007 A KR20157036007 A KR 20157036007A KR 101848819 B1 KR101848819 B1 KR 101848819B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
methyl
hydroxy
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157036007A
Other languages
English (en)
Korean (ko)
Other versions
KR20160003889A (ko
Inventor
브라이언 알빈 존스
타카시 카와스지
테루히코 타이시
요시유키 타오다
Original Assignee
비이브 헬쓰케어 컴퍼니
시오노기세야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101848819(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 비이브 헬쓰케어 컴퍼니, 시오노기세야쿠 가부시키가이샤 filed Critical 비이브 헬쓰케어 컴퍼니
Publication of KR20160003889A publication Critical patent/KR20160003889A/ko
Application granted granted Critical
Publication of KR101848819B1 publication Critical patent/KR101848819B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157036007A 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체 Active KR101848819B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2005-131161 2005-04-28
JP2005131161 2005-04-28
JP2005312076 2005-10-27
JPJP-P-2005-312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147017235A Division KR101580310B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Publications (2)

Publication Number Publication Date
KR20160003889A KR20160003889A (ko) 2016-01-11
KR101848819B1 true KR101848819B1 (ko) 2018-04-16

Family

ID=37215098

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157036007A Active KR101848819B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR1020147017235A Active KR101580310B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR1020077027734A Active KR101363875B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
KR1020137028203A Active KR101504998B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020147017235A Active KR101580310B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR1020077027734A Active KR101363875B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
KR1020137028203A Active KR101504998B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Country Status (30)

Country Link
US (22) US8129385B2 (OSRAM)
EP (9) EP2527007B1 (OSRAM)
JP (2) JP4295353B2 (OSRAM)
KR (4) KR101848819B1 (OSRAM)
AU (1) AU2006239177B8 (OSRAM)
BE (1) BE2021C519I2 (OSRAM)
BR (1) BRPI0610030B8 (OSRAM)
CA (1) CA2606282C (OSRAM)
CY (7) CY1115151T1 (OSRAM)
DK (6) DK3187225T3 (OSRAM)
EA (1) EA014162B1 (OSRAM)
ES (7) ES2446324T3 (OSRAM)
FI (1) FIC20210017I1 (OSRAM)
FR (1) FR14C0041I2 (OSRAM)
HK (2) HK1249742A1 (OSRAM)
HU (6) HUE037795T2 (OSRAM)
IL (4) IL186555A (OSRAM)
LT (5) LT3045206T (OSRAM)
LU (2) LU92446I2 (OSRAM)
MA (1) MA29460B1 (OSRAM)
MX (2) MX302718B (OSRAM)
NL (2) NL300676I2 (OSRAM)
NO (5) NO339525B1 (OSRAM)
NZ (1) NZ562339A (OSRAM)
PL (5) PL2465580T3 (OSRAM)
PT (5) PT3045206T (OSRAM)
SI (6) SI1874117T1 (OSRAM)
TW (1) TWI378931B (OSRAM)
VN (1) VN34404A1 (OSRAM)
WO (1) WO2006116764A1 (OSRAM)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100582109C (zh) 2003-12-24 2010-01-20 生物区科学管理控股有限公司 用于治疗呼吸道合胞体病毒感染的多环试剂
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
WO2006121831A2 (en) 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
AU2006307101A1 (en) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
RU2503679C2 (ru) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
SI2220076T1 (sl) 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
US8183372B2 (en) 2008-07-25 2012-05-22 Shionogi & Co., Ltd. Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines
SG192550A1 (en) * 2008-07-25 2013-08-30 Viiv Healthcare Co Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US8710249B2 (en) 2008-12-11 2014-04-29 Shionogi & Co., Ltd. Maltol ether processes and intermediates
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2376453B1 (en) 2008-12-11 2019-11-20 VIIV Healthcare Company Intermediates for carbamoylpyridone hiv integrase inhibitors
EP2376080B1 (en) 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
RS57244B1 (sr) 2009-06-15 2018-07-31 Shionogi & Co Supstituisani policiklički derivati karbamoilpiridona
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
EA032868B1 (ru) * 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
AU2014202405B2 (en) * 2010-01-27 2016-02-25 Viiv Healthcare Company Antiviral therapy
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
PH12012501689A1 (en) * 2010-02-26 2012-11-05 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
ES2608377T3 (es) 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN103228653B (zh) * 2010-09-24 2016-03-16 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
EP2742051B1 (en) * 2011-09-14 2016-10-12 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
BR112014008896A2 (pt) * 2011-10-12 2017-04-18 Shionogi & Co derivado de piridona policíclico tendo atividade inibidora de integrase
HRP20171665T1 (hr) 2011-12-28 2017-12-15 Global Blood Therapeutics, Inc. Supstituirani spojevi benzaldehida i metode za njihovu primjenu u povećanju oksigenacije tkiva
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
MX344879B (es) * 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
RU2015131006A (ru) * 2012-12-27 2017-01-30 Джапан Тобакко Инк. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970308B1 (en) 2013-03-15 2021-07-14 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015110897A2 (en) * 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106866702B (zh) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (OSRAM) 2014-03-20 2015-09-25 Cipla Ltd
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
NO2717902T3 (OSRAM) * 2014-06-20 2018-06-23
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016027879A1 (ja) * 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
CN107531614B (zh) 2015-02-06 2020-04-10 迈兰实验室有限公司 德罗格韦的制备方法
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (en) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
RU2712275C9 (ru) * 2015-04-28 2020-03-19 Сионоги Энд Ко., Лтд. Замещенные полициклические производные пиридона и их пролекарства
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (en) 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
DK3383392T3 (da) 2015-12-04 2025-08-18 Global Blood Therapeutics Inc Doseringsskema for 2.HYDROXY.6.((2.(1.ISOPROPYL.1H.PYRAZOL.5.YL)PYRIDIN.3.YL)METHOXY)BENZALDEHYD
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
ES2742249T3 (es) 2015-12-21 2020-02-13 Lupin Ltd Proceso para la preparación de inhibidores de la integrasa de VIH
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
WO2017223280A2 (en) * 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
WO2018031987A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20190216725A1 (en) * 2016-09-21 2019-07-18 Merck Shapr & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
EP3583107B1 (en) * 2017-02-16 2020-11-18 Sandoz AG Crystalline form of cabotegravir sodium
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
CN111386276B (zh) 2017-10-06 2023-06-23 盐野义制药株式会社 制备取代的多环吡啶酮衍生物的立体选择性方法
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
TWI880167B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三衍生物
AU2019277548B2 (en) 2018-05-31 2023-12-14 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
MY207622A (en) 2018-10-22 2025-03-06 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
JPWO2021107066A1 (OSRAM) 2019-11-28 2021-06-03
IL293566A (en) 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4208169A1 (en) 2020-09-01 2023-07-12 VIIV Healthcare Company Combination of cabotegravir and levonorgestrel
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
EP4255472A2 (en) 2020-12-07 2023-10-11 VIIV Healthcare Company Combination therapy
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
WO2022253294A1 (zh) 2021-06-03 2022-12-08 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
JP2024542776A (ja) 2021-12-03 2024-11-15 ヴィーブ、ヘルスケア、カンパニー （ｒ）－３－アミノブタン－１－オールの合成方法
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024153203A1 (en) * 2023-01-18 2024-07-25 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
WO2025068912A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058757A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2005016927A1 (ja) 2003-08-13 2005-02-24 Japan Tobacco Inc. 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
US6093732A (en) 1997-12-22 2000-07-25 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
EP1297834A4 (en) † 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
DE60128936T2 (de) 2000-10-12 2008-04-10 Merck & Co, Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
WO2003016275A1 (fr) 2001-08-10 2003-02-27 Shionogi & Co., Ltd. Agent antiviral
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1441735B1 (en) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP2045242A1 (en) 2002-08-13 2009-04-08 Shionogi&Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
AU2003267098B2 (en) * 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
JP2006528694A (ja) 2003-05-13 2006-12-21 スミスクライン ビーチャム コーポレーション ナフチリジンインテグラーゼインヒビター
WO2005015927A1 (en) * 2003-08-12 2005-02-17 Rachel Beijer Scheduled message service
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
AU2005211733A1 (en) 2004-02-11 2005-08-25 Shionogi & Co., Ltd HIV integrase inhibitors
CA2557926A1 (en) 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
AU2005227258A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. HIV integrase inhibitors
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) * 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
EP1866313A1 (en) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
US8129385B2 (en) * 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
EP1910363A4 (en) 2005-08-04 2010-05-26 Glaxosmithkline Llc INHIBITORS OF HIV INTEGRASE
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058757A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2005016927A1 (ja) 2003-08-13 2005-02-24 Japan Tobacco Inc. 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Also Published As

Publication number Publication date
ES2667868T5 (es) 2023-06-01
EP1874117A1 (en) 2008-01-09
ES2743531T3 (es) 2020-02-19
BE2021C519I2 (OSRAM) 2025-12-10
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
SI2465580T1 (sl) 2014-04-30
EP1874117B1 (en) 2013-08-28
MX312216B (en) 2013-08-12
JP2009079058A (ja) 2009-04-16
BRPI0610030B8 (pt) 2022-01-11
IL225207A (en) 2017-11-30
DK1874117T3 (da) 2013-09-23
NZ562339A (en) 2011-01-28
NO2017010I1 (no) 2017-03-27
ES2892304T3 (es) 2022-02-03
US9051337B2 (en) 2015-06-09
EP3045206B1 (en) 2018-03-28
EP2465580B1 (en) 2013-12-18
NO2017010I2 (no) 2017-03-27
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
AU2006239177A1 (en) 2006-11-02
EP2527007B1 (en) 2016-03-30
EP3187225A1 (en) 2017-07-05
EP2527007A1 (en) 2012-11-28
CY1124601T1 (el) 2022-07-22
NO339525B1 (no) 2016-12-27
BRPI0610030A2 (pt) 2011-10-11
PL3372281T3 (pl) 2021-12-27
EP1874117A4 (en) 2009-12-30
US8410103B2 (en) 2013-04-02
LUC00210I2 (OSRAM) 2022-10-07
JP4295353B2 (ja) 2009-07-15
WO2006116764A1 (en) 2006-11-02
DK3372281T3 (da) 2021-09-27
EP3284519A8 (en) 2018-04-18
PT3372281T (pt) 2021-10-14
US20200339598A1 (en) 2020-10-29
ES2906792T3 (es) 2022-04-20
HUS2100023I1 (hu) 2021-07-28
NO2023042I1 (no) 2023-11-08
SI3045206T1 (en) 2018-07-31
LTPA2021512I1 (OSRAM) 2021-07-12
KR101504998B1 (ko) 2015-03-23
AU2006239177B2 (en) 2011-10-20
LTC1874117I2 (lt) 2025-03-25
NL301109I2 (nl) 2021-09-15
US9273065B2 (en) 2016-03-01
US20170267693A1 (en) 2017-09-21
US8778943B2 (en) 2014-07-15
CY1115151T1 (el) 2015-12-09
EP3372281B1 (en) 2021-07-07
LTPA2014021I1 (lt) 2014-07-25
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
HUS2100022I1 (hu) 2021-07-28
CY1120345T1 (el) 2019-07-10
US20160207939A1 (en) 2016-07-21
US20190284208A1 (en) 2019-09-19
US11267823B2 (en) 2022-03-08
LU92446I2 (fr) 2015-10-29
PL2465580T3 (pl) 2014-05-30
US20120115875A1 (en) 2012-05-10
FIC20210017I1 (fi) 2021-06-10
NO340111B1 (no) 2017-03-13
CA2606282C (en) 2016-04-26
US20170260203A1 (en) 2017-09-14
NO20075165L (no) 2007-11-22
SI3372281T1 (sl) 2021-11-30
EP3045206A1 (en) 2016-07-20
LTC2465580I2 (OSRAM) 2022-10-10
NO2021018I1 (no) 2021-05-10
HK1251191A1 (en) 2019-01-25
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
PT1874117E (pt) 2013-10-17
ES2667868T3 (es) 2018-05-14
CY2021016I1 (el) 2021-10-15
US20170029438A1 (en) 2017-02-02
DK3187225T3 (da) 2022-02-28
EP3372281A1 (en) 2018-09-12
PT3045206T (pt) 2018-07-05
US20220213121A1 (en) 2022-07-07
HK1249742A1 (en) 2018-11-09
PL3284520T3 (pl) 2020-01-31
MA29460B1 (fr) 2008-05-02
LT3284520T (lt) 2019-09-25
NL300676I2 (OSRAM) 2016-10-11
DK3284520T3 (da) 2019-09-16
US20140200209A1 (en) 2014-07-17
IL215788A0 (en) 2011-12-29
PT3284520T (pt) 2019-09-10
US20170209454A1 (en) 2017-07-27
EP3284520A1 (en) 2018-02-21
ES2446324T3 (es) 2014-03-07
ES2567197T3 (es) 2016-04-20
US20090318421A1 (en) 2009-12-24
SI3284520T1 (sl) 2019-10-30
US20190152990A1 (en) 2019-05-23
EA200702080A1 (ru) 2008-04-28
US20240279238A1 (en) 2024-08-22
EP3045206B2 (en) 2023-02-15
US20160304535A1 (en) 2016-10-20
KR20160003889A (ko) 2016-01-11
ES2437268T3 (es) 2014-01-09
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
IL225206A (en) 2017-11-30
US20170145033A1 (en) 2017-05-25
HUS1400039I1 (hu) 2016-08-29
BRPI0610030B1 (pt) 2020-09-15
HK1172282A1 (en) 2013-04-19
JP2008540343A (ja) 2008-11-20
FR14C0041I2 (fr) 2015-11-13
CY2014024I1 (el) 2015-12-09
NL301109I1 (nl) 2021-09-15
IL186555A0 (en) 2008-01-20
KR20140097438A (ko) 2014-08-06
TWI378931B (en) 2012-12-11
US20150232479A1 (en) 2015-08-20
PL3045206T3 (pl) 2018-08-31
LT3045206T (lt) 2018-06-11
HUE037795T2 (hu) 2018-09-28
FR14C0041I1 (OSRAM) 2014-06-27
IL186555A (en) 2016-10-31
EP3284519A1 (en) 2018-02-21
CY1116331T1 (el) 2017-02-08
DK2465580T3 (en) 2014-03-10
EP3187226A1 (en) 2017-07-05
CY2014024I2 (el) 2025-05-09
MX302718B (es) 2012-08-27
SI1874117T1 (sl) 2014-01-31
HUE056603T2 (hu) 2022-02-28
US20170224695A1 (en) 2017-08-10
US20130172559A1 (en) 2013-07-04
EP3187225B1 (en) 2022-01-05
KR101580310B1 (ko) 2016-01-04
EA014162B1 (ru) 2010-10-29
US8129385B2 (en) 2012-03-06
CY2021016I2 (el) 2021-12-31
SI3187225T1 (sl) 2022-04-29
MX2007013351A (es) 2008-01-21
PL1874117T3 (pl) 2014-01-31
EP1874117B8 (en) 2014-03-12
TW200716635A (en) 2007-05-01
CY1122052T1 (el) 2020-10-14
US20170253616A1 (en) 2017-09-07
HUE044978T2 (hu) 2019-11-28
KR101363875B1 (ko) 2014-02-21
US20160137666A1 (en) 2016-05-19
EP2465580A1 (en) 2012-06-20
CA2606282A1 (en) 2006-11-02
US20170224694A1 (en) 2017-08-10
EP3284520B1 (en) 2019-06-05
AU2006239177B8 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
KR101848819B1 (ko) Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
CN101212903A (zh) 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
HK1230121A1 (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
HK1178473A (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151218

Application number text: 1020147017235

Filing date: 20140623

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151223

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160321

Patent event code: PE09021S01D

AMND Amendment
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160930

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170925

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160930

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20160321

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20171113

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170925

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180111

Appeal identifier: 2017101005462

Request date: 20171113

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20171113

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20171113

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170331

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20160523

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20180111

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20171218

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180409

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180410

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20200529

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20180409

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20200529

Decision date: 20201216

Appeal identifier: 2020100001641

J301 Trial decision

Free format text: TRIAL NUMBER: 2020100001641; TRIAL DECISION FOR INVALIDATION REQUESTED 20200529

Effective date: 20201216

PJ1301 Trial decision

Patent event code: PJ13011S05D

Patent event date: 20201216

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20200529

Decision date: 20201216

Appeal identifier: 2020100001641

PJ2001 Appeal

Patent event date: 20201216

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Appeal kind category: Invalidation

Decision date: 20220210

Appeal identifier: 2021200002144

Request date: 20210302

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 4

End annual number: 4

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20220207

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2020100001641

Request date: 20200529

Appeal kind category: Invalidation

Decision date: 20201216

J122 Written withdrawal of action (patent court)
PJ1202 Withdrawal of action (patent court)

Patent event code: PJ12021R01D

Patent event date: 20220317

Comment text: Written Withdrawal of Action

Decision date: 20220210

Request date: 20210302

Appeal identifier: 2021200002144

Appeal kind category: Invalidation

PR1001 Payment of annual fee

Payment date: 20220324

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230323

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240401

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250324

Start annual number: 8

End annual number: 8